APA
PLX icon

American Portfolios Advisors’s Protalix BioTherapeutics PLX Stock Holding History

American Portfolios Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$521 Hold
500
– – ﹤0.01% 3379
2022
Q2 		$545 Hold
500
– – ﹤0.01% 3379
2022
Q1 		$530 Buy
+500
New +$458 ﹤0.01% 3463

Other funds holding PLX

HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CPA
Capital Performance Advisors Walnut Creek, California $1.5B AUM 21.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

American Portfolios Advisors's PLX Position: Q3 2022 in Review

American Portfolios Advisors held its Protalix BioTherapeutics (PLX) position steady in Q3 2022 at 500 shares worth $521. The position accounts for ﹤0.01% of the portfolio, ranked #3379.

American Portfolios Advisors first reported a position in PLX in Q1 2022 and has held it in 3 quarters since. The position peaked at $545 in Q2 2022. 27 funds tracked by Wall St. Rank hold PLX as of Q3 2022.

  • American Portfolios Advisors held 500 shares of Protalix BioTherapeutics worth $521 as of Q3 2022.
  • American Portfolios Advisors left its Protalix BioTherapeutics share count unchanged in Q3 2022.
  • Protalix BioTherapeutics made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #3379 holding.
  • American Portfolios Advisors first reported a position in Protalix BioTherapeutics in Q1 2022 and has held it in 3 quarters since.
  • American Portfolios Advisors's Protalix BioTherapeutics position peaked at $545 in Q2 2022.
  • 27 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.